Related Experiment Video
Updated: May 7, 2026

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Poly-Ingredient Formulation Bresol(®) Ameliorates Experimental Chronic Obstructive Pulmonary Disease (COPD) in Rats
Mohamed Rafiq1, Gollapalle Lakshminarayanashastry Viswanatha, Dattatray Anturlikar Suryakanth
1Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka, India.
Abstract:
In the present study, the protective effect of Bresol(®) - a polyherbal formulation - was evaluated in an experimental model of cigarette smoke (CS)-induced COPD in rats. Ten minutes daily exposure to CS for 7 weeks caused significant elevation of TNF-α (p<0.01) and total protein (p<0.01) in the bronchoalveolar lavage fluid (BALF) of positive untreated control animals, indicating ongoing inflammatory process in the lungs. Further, histopathological findings have confirmed the presence of pathological lesions in the trachea and lungs. Five weeks of post-treatment with Bresol(®) (250 and 500 mg/kg, p.o.) showed significant and dose-dependent anti-inflammatory effects against CS-induced lung abnormalities by maintaining the TNF-α and total protein levels within the normal range. Additionally, Bresol(®)-treated animals showed normal cyto-architecture of the trachea and lungs. In conclusion, Bresol(®) showed dose-dependent protection against CS-induced lung and tracheal injury in rats, which further indicates, Bresol(®) is a useful healing agent, may help to decelerate the progression of COPD, and reduce the exacerbations in patients.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

